Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
P/B ratio for iTeos Therapeutics, Inc. (ITOS)
P/B ratio as of 2023: 0.68
According to iTeos Therapeutics, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.68. At the end of 2022 the company had a P/B ratio of 1.05.
P/B ratio history for iTeos Therapeutics, Inc. from 2018 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.68 |
| 2022 | 1.05 |
| 2021 | 2.96 |
| 2020 | 3.67 |
| 2019 | 42.58 |
| 2018 | 9.51 |